Literature DB >> 8525020

EORTC guidelines for writing protocols for clinical trials of radiotherapy.

M Bolla1, H Bartelink, G Garavaglia, D Gonzalez, J C Horiot, K A Johansson, G van Tienhoven, K Vantongelen, M van Glabbeke.   

Abstract

The concept of a Master Protocol for phase III studies was raised at the Steering Committee of the EORTC Radiotherapy Group, in order to make the work of the study coordinators easier, when writing protocols and to give them more homogeneity. The Master Protocol defines and clarifies in a logical order the different steps which must be taken when designing a randomized trial--from the rationale to the references. It pays particular attention to eligibility criteria, volumes of interest defined in agreement with ICRU Report 50 (gross tumor volume, clinical target volume, planning target volume and organs at risk), simulation procedure, treatment technique, normal tissue sparing, dose computation, equipment, dose specification (also in agreement with ICRU Report 50). Last but not least, the different procedures of quality assurance for protocols and patients are also defined (site visits, dummy run procedure, in vivo dosimetry, individual case review) to allow working plans to be made in advance. We are aware that this work is not exhaustive, but hope that the contents will be of help to those who are writing a protocol.

Entities:  

Mesh:

Year:  1995        PMID: 8525020     DOI: 10.1016/0167-8140(95)01573-y

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  3 in total

1.  Quality assurance of the EORTC Trial 22881/10882: boost versus no boost in breast conserving therapy. An overview.

Authors:  G van Tienhoven; B J Mijnheer; H Bartelink; D G González
Journal:  Strahlenther Onkol       Date:  1997-04       Impact factor: 3.621

2.  Development of a novel treatment planning test for credentialing rotational intensity-modulated radiotherapy techniques in the UK.

Authors:  Y Tsang; L Ciurlionis; C Clark; K Venables
Journal:  Br J Radiol       Date:  2013-02       Impact factor: 3.039

3.  Quality assurance analysis of participating centres' protocol compliance to a UK multicentre hypofractionated breast (FAST) trial.

Authors:  Y Tsang; K Venables; J Yarnold
Journal:  Br J Radiol       Date:  2012-01-31       Impact factor: 3.039

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.